Morgan Stanley Lian Bio Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$1.33 - $4.6 $1,337 - $4,627	1,006 New	1,006 $4,000
Q4 2023 Feb 13, 2024	BUY	$1.33 - $4.6 $6 - $23	5 Added 0.5%	1,006 $4,000
Q4 2022 Feb 14, 2023	SELL	$1.14 - $2.11 $61,725 - $114,245	-54,145 Reduced 98.18%	1,001 $1,000
Q3 2022 Nov 14, 2022	BUY	$1.87 - $3.0 $101,251 - $162,435	54,145 Added 5409.09%	55,146 $110,000
Q2 2022 Oct 27, 2022	SELL	$2.15 - $6.01 $6,488 - $18,138	-3,018 Reduced 75.09%	1,001 $2,000
Q2 2022 Aug 15, 2022	SELL	$2.15 - $6.01 $6,488 - $18,138	-3,018 Reduced 75.09%	1,001 $2,000
Q1 2022 Oct 27, 2022	BUY	$2.8 - $6.21 $8,450 - $18,741	3,018 Added 301.5%	4,019 $15,000
Q1 2022 May 13, 2022	BUY	$2.8 - $6.21 $11,253 - $24,957	4,019 New	4,019 $15,000

1.1M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $32.5M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.